Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era

American Journal of Transplantation

Volumn 8, Issue 6, 2008, Pages 1345-1348

  Karras, A ^a   De Lentdecker, P ^a   Delahousse, M ^a   Debauchez, M ^a   Tricot, L ^a   Pastural, M ^a   Bruneval, P ^b   Zemoura, L ^a   Duong Van Huyen, J P ^a,b   Lidove, O ^c  

^a FOCH HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Cardiac transplant; Cardiomyopathy; Fabry disease; Kidney transplantation

Indexed keywords

ALPHA GALACTOSIDASE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ANAMNESIS; AORTA STENOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LABORATORY TEST; LYMPHEDEMA; MALE; MITRAL VALVE DISEASE; NEUROPATHIC PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTOLIC HEART MURMUR; TREATMENT OUTCOME; TREATMENT RESPONSE; VALVULAR HEART DISEASE;

ADULT; ALPHA-GALACTOSIDASE; ENZYMES; FABRY DISEASE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE;

EID: 44449131442     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02245.x     Document Type: Article

References (18)

1. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003 138 : 338 346.
2. Eng CM, Guffon N, Wilcox WR et al. International collaborative Fabry disease study group. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001 345 : 9 16.
3. Grunfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis 2001 24 (2Suppl 71 74.
4. Cantor WJ, Daly P, Iwanochko M, Clarke JT, Cusimano RJ, Butany J. Cardiac transplantation for Fabry's disease. Can J Cardiol 1998 14 : 81 84.
5. Weidemann F, Breunig F, Beer M et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 2003 108 : 1299 1301.
6. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004 75 : 65 74.
7. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006 69 : 1216 1221.
8. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 2007 146 : 77 86.
9. Tahir H, Jackson L, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β. J Am Soc Nephrol 2007 18 : 2609 2617.
10. Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with Fabry disease. J Am Soc Nephrol 2002 13 (2Suppl S144 S146.
11. Ojo A, Meier-Kriesche HU, Friedman G et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000 69 : 2337 2339.
12. Inderbitzin D, Avital I, Largiader F, Vogt B, Candinas D. Kidney transplantation improves survival and is indicated in Fabry's disease. Transplant Proc 2005 37 : 4211 4214.
13. Gantenbein H, Bruder E, Burger HR, Briner J, Binswanger U. Recurrence of Fabry's disease in a renal allograft 14 years after transplantation. Nephrol Dial Transplant 1995 10 : 287 289.
14. Mignani R, Panichi V, Giudicissi A et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study. Kidney Int 2004 65 : 1381 1385.
15. Linhart A, Kampmann C, Zamorano JL et al. Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry outcome survey. Eur Heart J 2007 28 : 1228 1235.
16. Hughes DA, Elliott PM, Shah J et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 2008 94 : 138 139.
17. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007 22 : 1920 1925.
18. Narula J, Bennett LE, DiSalvo T, Hosenpud JD, Semigran MJ, Dec GW. Outcomes in recipients of combined heart-kidney transplantation: Multiorgan, same-donor transplant study of the International Society of Heart and Lung. Transplantation 1997 Mar 27 63 : 861 867.